Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16082980 | 1.00 | ATF4 (1.00) | ATF4LMNAKMT2AHPGDHTT | |
| SCHEMBL16083047 | 1.00 | ATF4 (1.00) | ATF4LMNAKMT2AHPGDHTT | |
| SCHEMBL17658630 | 0.94 | ATF4 (0.89) | ATF4LMNAKMT2AHPGDHTT | |
| SCHEMBL17658580 | 0.94 | ATF4 (0.89) | ATF4LMNAKMT2AHPGDHTT | |
| SCHEMBL17658492 | 0.93 | ATF4 (0.86) | ATF4LMNAKMT2AHPGDHTT | |
| SCHEMBL17658626 | 0.93 | ATF4 (0.86) | ATF4LMNAKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL16082960 | 0.93 | ATF4 (0.86) | ATF4LMNAKMT2AHPGDHTT | |
| SCHEMBL17658683 | 0.93 | ATF4 (0.86) | ATF4LMNAKMT2AHPGDHTT | |
| SCHEMBL21050163 | 0.93 | ATF4 (0.86) | ATF4LMNAKMT2AHPGDHTT | |
| SCHEMBL21050166 | 0.93 | ATF4 (0.86) | ATF4LMNAKMT2AHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632208-A1 | CELL STABILIZATION | Biomatrica, INC. (US) | 2020-04-08 | — | — | EP | claimed |
| US-20160135446-A1 | CELL STABILIZATION | MXCGLOBAL INC. | 2016-05-19 | — | — | US | claimed |
| EP-3007556-A2 | CELL STABILIZATION | Biomatrica, INC. (US) | 2016-04-20 | — | — | EP | claimed |
| WO-2015002729-A2 | CELL STABILIZATION | BIOMATRICA, INC. (US) | 2015-01-08 | — | — | WO | claimed |
| EP-3368037-B1 | NOVEL METHODS OF TREATING HEARING LOSS | UNIV CALIFORNIA (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250114470-A1 | THERAPY FOR POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF MASSACHUSETTS | 2025-04-10 | — | — | US | disclosed |
| WO-2025059689-A1 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF PHARYNGEAL FOREGUT ENDODERM AND ITS DERIVATIVES | UNIVERSITY OF MASSACHUSETTS (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20240390323-A1 | NOVEL METHODS OF TREATING HEARING LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-11-28 | — | — | US | disclosed |
| US-20240268372-A1 | Methods and Compositions for Extending Organ and Tissue Preservation | MASSACHUSETTS GEN HOSPITAL (US) | 2024-08-15 | — | — | US | disclosed |
| US-11957655-B2 | Methods of treating hearing loss | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240043473-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | PHOENIX NEST INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4291237-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | Phoenix Nest Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20170342020-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-11-30 | — | — | US | disclosed |
| US-20170342020-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-11-30 | — | — | US | disclosed |
| US-9708247-B2 | Modulators of the eIF2alpha pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160135446-A1 | CELL STABILIZATION | MXCGLOBAL INC. | 2016-05-19 | — | — | US | disclosed |
| EP-3007556-A2 | CELL STABILIZATION | Biomatrica, INC. (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160096800-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-04-07 | — | — | US | disclosed |
| WO-2015002729-A2 | CELL STABILIZATION | BIOMATRICA, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| WO-2014144952-A2 | MODULATORS OF THE EIF2ALPHA PATHWAY | WALTER PETER (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160135446-A1 | CELL STABILIZATION | CALR, CALU, TREH | ATF4 537/4885LMNA 330/4885KMT2A 4655/4885 |
| US-20170342020-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | EIF2AK1, EIF2A, EIF2AK3 | ATF4 7/4885LMNA 3251/4885KMT2A 3254/4885 |
| US-11957655-B2 | Methods of treating hearing loss | ATP2A1, ATP2A3, ATP2A2 | ATF4 5/4885LMNA 532/4885KMT2A 4628/4885 |
| US-20160096800-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | EIF2AK1, EIF2A, EIF2AK3 | ATF4 7/4885LMNA 3251/4885KMT2A 3254/4885 |
| US-20240390323-A1 | NOVEL METHODS OF TREATING HEARING LOSS | ATP2A1, ATP2A2, ATP2A3 | ATF4 5/4885LMNA 749/4885KMT2A 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.